Trial · NCT01929317
Results by group381
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 381
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at Week 12 in the CR High-dose Group | Ropinirole CR - High Dose Group | -4.8 | Standard Deviation 5.95 | Scores on a scale | |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - High Dose Group | Week 2 | -2.9 | Standard Deviation 4.41 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - Maintenance Dose Group | Week 2 | -2.7 | Standard Deviation 4.27 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - High Dose Group | Week 4 | -3.8 | Standard Deviation 5.23 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - Maintenance Dose Group | Week 4 | -4.4 | Standard Deviation 3.50 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - High Dose Group | Week 6 | -4.6 | Standard Deviation 5.28 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - Maintenance Dose Group | Week 6 | -5.0 | Standard Deviation 5.09 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - High Dose Group | Week 8 | -5.2 | Standard Deviation 5.46 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - Maintenance Dose Group | Week 8 | -4.5 | Standard Deviation 4.94 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - High Dose Group | Week 12 | -4.8 | Standard Deviation 5.95 | Scores on a scale |
| Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits | Ropinirole CR - Maintenance Dose Group | Week 12 | -5.7 | Standard Deviation 5.18 | Scores on a scale |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - High Dose Group | Week 2, 30% or greater reduction from Baseline | 10 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - Maintenance Dose Group | Week 2, 30% or greater reduction from Baseline | 4 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - High Dose Group | Week 4, 30% or greater reduction from Baseline | 17 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - Maintenance Dose Group | Week 4, 30% or greater reduction from Baseline | 5 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - High Dose Group | Week 6, 30% or greater reduction from Baseline | 21 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - Maintenance Dose Group | Week 6, 30% or greater reduction from Baseline | 6 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - High Dose Group | Week 8, 30% or greater reduction from Baseline | 30 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - Maintenance Dose Group | Week 8, 30% or greater reduction from Baseline | 7 | Participants | |
| Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase | Ropinirole CR - High Dose Group | Week 12, 30% or greater reduction from Baseline | 27 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01929317/results